Cargando…

Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients

BACKGROUND: Overexpression of RRM1 and RRM2 has been associated with gemcitabine resistance. BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus docetaxel in advanced non...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boukovinas, Ioannis, Papadaki, Chara, Mendez, Pedro, Taron, Miquel, Mavroudis, Dimitris, Koutsopoulos, Anastasios, Sanchez-Ronco, Maria, Sanchez, Jose Javier, Trypaki, Maria, Staphopoulos, Eustathios, Georgoulias, Vassilis, Rosell, Rafael, Souglakos, John
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579656/ https://www.ncbi.nlm.nih.gov/pubmed/19002265 http://dx.doi.org/10.1371/journal.pone.0003695

Ejemplares similares

Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide
por: Karachaliou, Niki, et al.
Publicado: (2013)

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
por: Souglakos, J, et al.
Publicado: (2008)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2019)

RRM1 *151A>T, RRM1 ‐756T>C, and RRM1 ‐585T>Gis associated with increased susceptibility of lung cancer in Chinese patients
por: Xu, Xiao‐Ling, et al.
Publicado: (2016)

Impact of KRAS, BRAF, PIK3CA Mutations, PTEN, AREG, EREG Expression and Skin Rash in ≥2(nd) Line Cetuximab-Based Therapy of Colorectal Cancer Patients
por: Saridaki, Zacharenia, et al.
Publicado: (2011)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2014)

Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma
por: Zhao, Li-Ping, et al.
Publicado: (2012)

The Clinical and Prognostic Significance of Ribonucleotide Reductase Subunits RRM1 and RRM2 mRNA Levels in Patients with Chronic Lymphocytic Leukemia
por: Chatzidavid, Sevastianos, et al.
Publicado: (2023)

RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine
por: Chen, Ying, et al.
Publicado: (2018)

Structural study of the Fox-1 RRM protein hydration reveals a role for key water molecules in RRM-RNA recognition
por: Krepl, Miroslav, et al.
Publicado: (2017)

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment
por: Cheng, Bisheng, et al.
Publicado: (2023)

Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells
por: Kato, Tomotaka, et al.
Publicado: (2021)

RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer
por: Ono, Hiroaki, et al.
Publicado: (2023)

Independent prognostic implications of RRM2 in lung adenocarcinoma
por: Ma, Chao, et al.
Publicado: (2020)

Zinc Binds to RRM2 Peptide of TDP-43
por: Golovin, Andrey V., et al.
Publicado: (2020)

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
por: Zhang, Keqiang, et al.
Publicado: (2009)

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient
por: Mlak, R., et al.
Publicado: (2015)

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021)

SLIRP stabilizes LRPPRC via an RRM–PPR protein interface
por: Spåhr, Henrik, et al.
Publicado: (2016)

Structural basis of IMP3 RRM12 recognition of RNA
por: Jia, Min, et al.
Publicado: (2018)

TIA-1 RRM23 binding and recognition of target oligonucleotides
por: Waris, Saboora, et al.
Publicado: (2017)

Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer
por: Zhou, Zijian, et al.
Publicado: (2022)

Deciphering the RRM-RNA recognition code: A computational analysis
por: Roca-Martínez, Joel, et al.
Publicado: (2023)

A missense mutation in RRM1 contributes to animal tameness
por: Dou, Mingle, et al.
Publicado: (2023)

The Expression of ERCC1, RRM1, and BRCA1 in Breast Cancer According to the Immunohistochemical Phenotypes
por: Kim, Dokyung, et al.
Publicado: (2011)

BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome
por: Saridaki, Zacharenia, et al.
Publicado: (2013)

A Kinome Screen Identifies Checkpoint Kinase 1 (CHK1) as a Sensitizer for RRM1-Dependent Gemcitabine Efficacy
por: Zhou, Jun, et al.
Publicado: (2013)

Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
por: Xia, Guanggai, et al.
Publicado: (2017)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2020)

The structure and selectivity of the SR protein SRSF2 RRM domain with RNA
por: Phelan, Marie M., et al.
Publicado: (2012)

RRM2 is a potential prognostic biomarker with functional significance in glioma
por: Sun, Hongzhi, et al.
Publicado: (2019)

ATP binds and inhibits the neurodegeneration-associated fibrillization of the FUS RRM domain
por: Kang, Jian, et al.
Publicado: (2019)

Histone chaperones and the Rrm3p helicase regulate flocculation in S. cerevisiae
por: Rowlands, Hollie, et al.
Publicado: (2019)

Identification and Characterization of an RRM-Containing, RNA Binding Protein in Acinetobacter baumannii
por: Ciani, Caterina, et al.
Publicado: (2022)

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine
por: Ulker, Mehmet, et al.
Publicado: (2015)

MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy
por: Lu, Huimin, et al.
Publicado: (2019)

RNA recognition and self-association of CPEB4 is mediated by its tandem RRM domains
por: Schelhorn, Constanze, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j5isj2v5puo8bscuesbf2justs